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"Proliferative skin disease" is a phrase which we 
define to include all skin diseases characterized by 
an abnormal proliferation of epidermal keratino-
cytes. Such diseases include psoriasis , cancer, 
eczema, and ichthyosis . Although these prolifera-
tive entities probably have multiple etiologies, the 
universality of common physiologic mechanisms 
implies that the molecular basis of cellular prolif-
eration has mechanisms common to all cells. Deci-
phering these fundamental mechanisms is basic to 
the understanding of normal and abnormal cellular 
proliferation in tissues . 
MOLECULAR BIOLOGY OF CELL PROLIFERATION 
A starting point for the study of cell proliferation 
lies in a consideration of the central dogma of 
molecular biology. The central dogma, as stated by 
Crick, says that the genetic material DNA codes 
for RNA in a process called transcription and RNA 
supplies the transient intermediate code by which 
proteins are synthesized in a process termed trans-
lation. Thus, nucleic acids specify proteins in a 
unidirectional transfer of information. The other 
cellular process in which DNA participates is 
replication whereby DNA makes additional copies 
of itself to be transmitted to progeny cells [1].* The 
aim of molecular biology is to understand in fine 
detail the reactions in which DNA participates. A 
corollary of this argument is that aberrant cell 
proliferation could be said to be the result of 
derangements of either transcription , translation , 
or replicative processes. 
Cells in their lifetime essentially undergo two 
general types of processes: differentiation and 
proliferation. By differentiation we mean the selec -
tive activation of specific functions unique to a 
particular cell type. Thus an epidermal cell is 
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specialized to meet the demands of the epidermis 
and not those of the kidney. Since all cells carry 
the same genetic complement [2], the concept of 
differentiation implies the selective activation or 
repression of genes. How this modification of gene 
activity is accomplished is beyond the scope of this 
paper and we shall focus on the process of prolifera-
tion (remembering, however, that in the living cell 
the two processes are coupled). In terms of the 
central dogma as stated above, differentiation 
implies processes in which RNA and proteins are 
made to perform specialized functions, whereas the 
proliferative processes lead to duplication of ge-
netic material and production of progeny cells. 
The Cell Cycle 
The concept of the cell cycle was first put forth 
by Howard and Pelc [3] and is based on the fact 
that DNA is synthesized at a specific time (S 
phase) by a proliferating eukaryotic cell. Figure 1 
illustrates the phases of the cell cycle as they relate 
to the S phase. Thus , G 1 (G stands for gap) 
represents the time from the end of the previous 
mitosis until DNA synthesis begins in S phase; G 2 
represents the time from the completion of DNA 
synthesis until the beginning of the next mitosis; 
M represents the stage of mitosis. The concept of 
the cell cycle exists for normally proliferating cells 
[4]. Some cells, like neurons in their adult life or 
epidermal cells in the stratum granulosum , never 
cycle and therefore are said to be terminally 
differentiated. The ability of cells that are termi-
nally differentiated to re-enter the cycle often 
relates to a pathologic process , i.e., neurons enter 
the cell cycle to become malignant neuroblastoma 
cells. In normal non proliferating cells, cells are 
said to be "blocked" and cannot pass through G 1 
[5]. Diseases of cellular proliferation may owe their 
pathology to the aberrant activation of the prolifer-
ative apparatus. The amount of time that prolifer-
ating cells spend in the various stages of the cell 
cycle varies according to the cell [4,6]. A generali-
zation that is often made is that most variations 
really occur in the G 1 phase. 
The Proliferative Program-Molecular Events 
Occurring During the · Cell Cycle 
An ordered sequence of proliferation as defined 
by a cell cycle implies a "proliferative program. " 
The molecular events in this proliferative program 
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FIG. 1. The stages of the cell cycle and their relation-
ship to the " proliferative" and "differentiation" pro-
grams. (See text for detailed explanation.) 
are currently being closely scrutinized m many 
laboratories [5]. 
The initial signal. The nature of the proliferating 
signal remains unknown at present. However, 
some evidence points to a role either in initiation or 
transmission of that signal by cyclic nucleotides. 
Pastan and his colleagues [7] have observed that 
malignant fibroblasts contain lowered le'vels of 
3'5'-cyclic adenosine monophosphate (cAMP) and 
addition of exogenous cAMP results in a phenoty-
pic alteration of the malignant state towards 
normal. In lymphocytes and lymphosarcoma cells, 
cell proliferation in response to mitogens is sup-
pressed by cAMP; and a current hypothesis is that 
maintenance of the G I block is related to the ratio 
of cAMP to cGMP (3'5'-cyclic-guanosine mono-
phosphate) in the cell such that high amounts of 
cAMP serve to modulate the nonproliferating state 
[8] . 
Proliferation may be favored by increased cGMP 
levels. Thus Chambers and his colleagues [9,10] 
have been able to show that cGMP itself, as well as 
its more permeable derivatives , can act as a weak 
mitogenic agent for lymphocytes. Hadden et al 
[11] have shown that the addition of mitogens to 
lymphocytes leads to rapid, dramatic increases in 
intracellular levels of cGMP. Additional evidence 
of Seifert and Rudland [12] shows that cG MP 
levels are increased in proliferating fibroblasts. 
In addition to cyclic nucleotides, prostaglandins 
and a number of protein factors have been impli-
cated as modulators of the proliferative process 
and may be involved in the initiating signal (see 
below) . 
G I phase of the cell cycle. During the G I portion 
of the cell cycle, the cell prepares to synthesize the 
substrates, enzymes, and proteins necessary to 
support DNA synthesis and mitosis. A cell amena-
ble to the study of these processes is the lym-
phocyte because lymphocytes are resting cells 
which can be activated by mitogens to enter the 
cell cycle. (For a recent review, see [13 ].) Using the 
lymphocyte as a model, one can see an orderly 
preparation of cells for DNA synthesis. Some early 
events in G I appear to be increases in cellular 
levels of cGMP, increased histone phosphoryla-
tion, increased ribosomal RNA synthesis, de novo 
synthesis of purines and pyrimidines, increased 
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polyamine synthesis, and induction of enzymes 
[14]. The concomitant addition of cAMP and 
mitogen appears to repress these cellular events. 
Thus, G I is the period in the cell cycle in which 
cellular adaptation for DNA synthesis (e.g., syn-
thesis of deoxyn ucleotides) takes place. Some evi-
dence exists that a class of inducible enzymes is 
synthesized which are specifically adapted for 
cellular proliferation .' Thus Chambers et al [9] 
have shown that a specific phosphoribosyl pyro-
phosphate synthetase is induced 8 hr after entry of 
lymphocytes into G I , which differs from that found 
in the resting cells by being allosterically activati-
ble by cG MP. Green and Martin [15] have also 
documented the presence of this enzyme in hepatic 
tumor cells. The role of cGMP allosterically activa-
tible enzymes, which are probably important to 
cell proliferation, is under investigation in our 
laboratory. 
S phase. During S phase, DNA polymerase 
duplicates DNA concomitant with histone synthe-
sis. Histone synthesis appears to be coupled with 
nuclear DNA synthesis since inhibition of DNA 
synthesis leads to cessation of histone synthesis 
[4 ]. 
G2 phase. An active RNA metabolism is main-
tained during the G 2 phase of the cell cycle. During 
this phase cellular components necessary for mito-
sis and cytokinesis are synthesized [6]. 
M phase. In mitosis, cells go through the process 
of division and cytokinesis . It is of interest that no 
RN A synthesis occurs during mitosis. This could 
be interpreted to mean either that all proteins 
necessary to mitosis are synthesized prior to M 
phase or that messenger RNA molecules remain 
and are translated during this phase [4]. 
Differentiation and Go. At the termination of 
mitosis, there are two progeny cells. These cells can 
continue to cycle, enter Go, or differentiate [6]. 
How these cellular decisions are made is not 
known . Furthermore, proliferating cells still retain 
the majority of their differentiated functions. The 
detailed understanding of the relationship of dif-
ferentiation to proliferation represents an enigma 
which cell biologists must solve . 
THE EPIDERMIS IN THE PROLIFERATIVE PROGRAM 
Wound Healing 
A normal physiologic analog of proliferative skin 
disease is the process of wound healing, in which 
the organism responds to injury by "directed 
proliferation" [16]. The normal epidermis adjusts 
the rate between proliferation and differentiation 
to achieve a steady state. However, as a result of 
wounding, the epidermis must increase the rate of 
proliferation to meet the new demand. The charac-
teristics of the proliferating epidermis responding 
to a wound are increased cellular glycogen content, 
increased rate of proliferation, and migration of the 
epithelial cells into the area of the wound. These 
characteristics are consistent with a mechanism 
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involving a decrease in the levels of cAMP and an 
increase in the levels of cGMP [17,18]. Evidence 
that altered cAMP metabolism occurs in epider-
mal wound healing has been noted by Williams 
[19], who observed that epidermal glycogen 
accumulation, increased proliferative rate, and 
cellular migration were decreased or eliminated 
by injecting into the areas near the wound either 
dibutyryl cAMP, or agents ~which increased cellu-
lar levels of cAMP such as epinephrine or theo-
phylline. 
The study of platelet interaction with endotheli-
al tissue may shed light on wound healing as well. 
Platelets respond to endothelial injury by aggre-
gating at the site of injury to seal the wound 
temporarily. Cell proliferation of the endothelial 
cells of the vessel wall ensues to achieve permanent 
repair. Data obtained from a cell culture system 
[20] indicate that an extract obtained from plate-
lets appears to activate endothelial cellular prolif-
eration. Gospodarowicz et al [21] have also ob-
served a similar or identical factor in Balb/3T3 
cells. At the time of this writing, it is still unsettled 
as to whether such factors are mediated through 
cyclic nucleotides, but a cyclic nucleotide-related 
mechanism would be consistent with the data cited 
above. 
Psoriasis 
Psoriasis is the prototype of common prolifera-
tive skin disease afflicting approximately 2% of the 
population [22]. Although psoriasis has compo-
nents (e.g., inflammation) other than increased 
epidermal proliferation, the most important aspect 
clinically is proliferation. Most, if not all, psoriasis 
has a genetic aspect which is probably multifac-
torial [23]. These genes in concert with unknown 
environmental factors, either exogenous or endoge-
nous, permit the epidermis to undergo increased 
cell proliferation. This proliferation may occur as a 
consequence of events such as skin injury or 
emotional stress. Although there is little suggestion 
that the increased epidermal proliferation of pso-
riasis results from immunologically derived stim-
uli, this situation accrues from a paucity of 
research on immunologic phenomena in psoriasis. 
We are concentrating our research on the epider-
mal proliferative component of this disease, since 
it is probable that the disease would be of little or 
no clinical consequence if the proliferative com-
ponent could be prevented or reversed. However, 
there is no reason to believe that causes of the 
epidermal proliferation could not be of extraepi-
dermal origin. At least four factors are important 
to our approach to the proliferative component of 
this disease: epidermal lesional glycogen accumu-
lation [24], increased epidermal proliferation [25], 
reduced epidermal differentiation [26], and abnor-
mal cell surface characteristics [27,28]. For reasons 
to be discussed, we believe that an elevated ratio of 
cGMP to cAMP may be central to the initiation 
and/or maintenance of these abnormal epithelial 
characteristics of the psoriatic lesion. 
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cAMP and cGMP in psoriasis. In 1970 we 
hypothesized that reduced levels of cAMP in the 
entire psoriatic lesional epidermis might account 
for the simultaneous existence of increased cell 
proliferation, reduced differentiation, and glycogen 
accumulation in the lesion [29]. This hypothesis 
developed from three observations: Biirk [30] had 
reported that polyoma-transformed cells had re-
duced adenylate cyclase activity; Johnson et al 
[31] showed that cAMP added to sarcoma cells 
slowed their growth and increased morphologic 
differentiation; and Robison et al [32] stated that 
glycogen levels were maintained at a "normal" 
concentration in several tissues or were reduced by 
cAMP. In support of the hypothesis we showed 
that dibutyryl cAMP inhibited epidermal cell 
division [33], an observation that has been con-
firmed by several laboratories [34-36]. Further-
more , we showed that the mean levels of cAMP 
were 36% lower in involved areas than in unin-
volved areas based on DNA as a data base using 
two different analytical techniques in 50 psoriatic 
patients [37 ,38]. 
DN A, protein, and wet weight were the three 
denominators utilized in conjunction with the two 
analytical methods (25 patients in each group) and 
resulted in six different percentage decreases in 
lesional cAMP levels. Of the six, five of the 
decreases were statistically significant and one, 
wet weight using the Gilman binding assay [39], 
was not (p = 0.09). These data and the uncertain-
ties of the denominators (for a review of this 
problem see [40]) led us to the likely conclusion 
that there was a decrease in the cAMP levels in 
lesional epidermis. 
In 1972 Hadden et al [11] showed that mitogen-
stimulated lymphocytes exhibited a marked rise in 
cGMP levels with no change in cAMP levels. This 
observation prompted us to measure the levels of 
cGMP in involved versus uninvolved psoriatic 
epidermis [41]. As in the stimulated lymphocytes, 
the lesional levels of cG MP were significantly 
increased. This finding led to a modification of our 
original hypothesis such that the current hypothe-
sis states that the reduction in the cAMP/cGMP 
ratio is central to the initiation and/or mainte-
nance of the aforementioned lesional abnormali-
ties. This hypothesis is an adaptation to the skin of 
Goldberg and associates' [42] original dualism 
hypothesis of biologic regulation through the 
opposing actions of cAMP and cGMP. In the case 
of cell proliferation, cAMP is viewed as the "off" 
and cGMP the "on" signal [8]. Subsequently, 
exogenous addition of cGMP has been shown to 
stimulate lymphocyte proliferation [10] and addi-
tion of serum to quiescent cells in culture results in 
cell proliferation and a concomitant decrease in the 
cAMP /cGMP ratio [43]. (For further review of 
cyclic nucleotide involvement in the regulation of 
proliferation and differentiation, see (7,17,18,44, 
45 ].) 
If one assumes that the cyclic nucleotides are of 
importance in the control of proliferation and 
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differentiation, then the question arises as to 
whether the fluctuations in cyclic nucleotide levels 
in psoriatic lesions are specific to the lesions or are 
found in other tissues as well. 
Some recent experiments of Ogden and Krueger 
[46] bear on this point. These investigators have 
reported a 250% increase in hexose mono phosphate 
shunt activity in mononuclear leukocytes of 
patients with severe psoriasis (greater than a 20% 
skin involvement) and a 47% increase in activity in 
leukocytes from patients with mild psoriasis (less 
than 20% "kin involvement). Shunt activity has 
been found to be increased in psoriatic lesions [47]. 
Other investigators [48,49] have suggested that 
shunt activity may be regulated by cyclic nucleo-
tides. The work of Ogden and Krueger suggests 
that altered cyclic nucleotide metabolism in 
patients with psoriasis may have manifestations in 
cells other than the epidermis. 
During the course of our laboratories ' investiga-
tion into the role of the cyclic nucleotides in 
psoriasis, two other laboratories [50,51] have pre-
sented data on cAMP in psoriasis which contrasts 
with that discussed above. 
Harkonen et al [50] reported a 54 % reduction in 
adenylate cyclase activity and a 36% reduction in 
the fluoride-stimulated adenylate cyclase activity 
in the lesion as compared with uninvolved areas. In 
the same paper these authors reported a 29 % 
increase in cAMP levels per kilogram wet weight in 
psoriatic lesions. Wright et al [52] found a 63 % 
reduction in the adenylate cyclase activity in 
lesional versus uninvolved epidermis in response to 
fluoride stimulation. Yoshikawa et al [53], using 
their modification of the Gilman cAMP assay [54], 
reported a normal level or a 24 to 27 % increase in 
lesional cAMP levels depepding upon the data 
base utilized. Halprin et al [51] have also found 
that the elevated glycogen content of lesional 
epidermis is lowered by cAMP. 
Without violating Ocham's razor, we are unable 
to understand how markedly reduced adenylate 
cyclase activity can be compatible with normal or 
increased cAMP levels; or how a high glycogen 
content can exist simultaneously in a tissue with 
increased levels of cAMP when cAMP is capable of 
reducing glycogen levels in lesional psoriatic epi-
dermis. Furthermore, the situation is inconsistent 
with studies from our laboratory in which we have 
found no convincing evidence of defective cAMP-
forming capacity in the lesions [38]. Our prelimi-
nary study (performed in 6 patients) of the low Km 
form of cAMP phosphodiesterase activity indicates 
an approximately fourfold increase in the V max of 
the enzyme with no change in the apparent Km of 
the enzyme [17]. Increased low Km cAMP phos-
phodiesterase activity also has been observed in 
neoplastic liver cells [55]. 
If our continuing studies of cAMP phosphodies-
terase in psoriasis confirm our preliminary data, it 
is reasonable to suggest that the decreased lesional 
levels of cAMP that we have reported are the result 
of misregulated cAMP hydrolysis. It seems quite 
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possible that the inconsistencies in the cAMP 
metabolic data can be resolved by standardization 
of the experimental procedures in the laboratories 
concerned. It is clear that although there is little 
agreement on the details, deranged cAMP metabo-
lism is indicated by the data from all investigators. 
Taken together with our cGMP data, we contend 
that the cAMP/cGMP ratio is reduced. Since this 
seems to be a reasonable assumption, the critical 
information needed relates to the functional role of 
cAMP and cGMP in epidermal homeostasis (the 
balance between proliferation and differentiation). 
Such information on their functional role may be 
far more important than their steady state or 
transient levels. 
In addition to obtaining data conr~erning the 
functional role of the cyclic nucleotides, more 
knowledge must be gained with regard to the 
specific agents that modulate the cyclic nucleotide 
systems in the epidermis. Several protein factors 
have been isolated from different sources which 
appear to increase cellular proliferation in tissue 
culture systems. These factors include fibroblast 
growth factor, epidermal growth factor, mesenchy-
mal factor, and tumor angiogenesis factor [56]. 
Work on such factors is still at a rather preliminary 
stage and must be viewed with some caution since 
serum itself contains a plethora of substances (e.g., 
insulin) which augment growth in tissue culture 
systems. Whether such a circumstance holds under 
in vivo conditions is not known. Nevertheless, 
considering the occurrence of growth and prolifera-
tion factors, it is certainly plausible that the 
abnormal release or presence of such agents could 
playa role in the more proximate pathophysiology 
of psoriasis. 
Prostaglandins and epidermal proliferation. 
Recent evidence shows that prostaglandins are 
important molecules in the modulation and main-
tenance of cyclic nucleotide metabolism. Prosta-
glandins (PGs) of the E series can regulate cAMP 
levels [57], while those of the F series regulate 
cGMP levels in the bovine vein [58]. Furthermore, 
PGE2 induces differentiation and reduces prolifera-
tion of neuroblastoma cells [59], whereas PGF 2cr 
stimulates 3T3 cells to proliferate in vitro [60]. 
PGE 2 inhibits epidermal cell proliferation in cul-
ture [61] and elevates epidermal cAMP levels in 
vitro [38]. These observations prompted us to 
examine PG metabolism in psoriasis. ' 
In collaboration with Hammarstrom et al [62] 
the levels of PGE2, PGF 2a, their precursor arachi-
donic acid, and HETE, a metabolic product of 
arachidonic acid recently discovered in platelets by 
Hamberg and Samuelsson [63], were measured in 
involved and uninvolved psoriatic epidermis by gas 
liquid chromatography-mass spectrometry. In 
involved versus uninvolved epidermis, the PGE2 
and PG F 2cr levels were 40% and 86% increased, 
respectively. Thus, although the absolute levels of 
both PG E 2 and PG F 2cr are elevated in the lesion, 
the PGF 2cr/PGE 2 ratio is also elevated. In involved 
versus uninvolved epidermis, the endogenous 
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levels of free arachidonic and HETE showed mean 
increases of 25-fold and 81-fold, respectively, 
pointing to a previously unrecognized perturbation 
in the control of free arachidonic acid levels. These 
results indicate that the increased levels of PGE2, 
PGF 2a and HETE may be secondary to the mark-
edly increased endogenous levels of arachidonic 
acid in the lesions. Since the formation of arachi -
donic acid from phospholipid is catalyzed by 
phospholipase A2 [64,65], the regulation of this 
enzyme in psoriatic and normal epidermis is under 
current investigation. 
The question as to how the minimal increases of 
PGE2 and PGF 2a in the lesions relate to the large 
increase in arachidonic acid is unknown. One 
possible explanation might be the presence of an 
inhibitor of PG biosynthesis such as that recently 
described in psoriatic plaques by Penneys et al 
[66]. The elevated levels of PGE2 might be ex-
pected to increase intracellular levels of cAMP. 
However, Newcombe et al [67] have proposed that 
cells may be less sensitive to PGs in vivo in 
situations of severe inflammation and altered cell 
proliferation. In fact, a relative lack of sensitivity 
of involved versus uninvolved psoriatic epidermis 
to PGE 1 - and PGE2-induced cAMP accumulation 
has been suggested [68-70]. 
An interesting animal model for investigating 
the interrelationship between PGE 2 and prolifera-
tive skin disease is the essential fatty acid (EFA)-
deficient rat which develops a scaly dermatosis. 
The skin of these animals contains low levels of 
PGE2 [71], a decreased ability to transform arachi-
donic acid into PGE 2 , and increased cell prolifera-
tion [72] . The topical application of PGE2 clears 
the scaly dermatosis leaving a histologically nor-
mal-appearing epidermis. Whether this return to 
normal involves an elevation of cAMP is unknown. 
The deranged PG metabolism in psoriasis and in 
scaly dermatosis of EF A deficiency suggests that 
PGs may be a prerequisite for epidermal homeo-
stasis. 
Cell surface and psoriasis. The cell surface of 
involved psoriatic epidermis appears altered from 
that of normal epidermis [27 ,28]. Ultrastructural 
studies showed a marked reduction in glyco-
protein-rich cell surface material in the mid-layers 
of involved epidermis in comparison with unin-
volved epidermis. Alterations of cell surface con-
stituents can alter the levels of cAMP [73], and 
cAMP levels can alter the composition of the cell 
surface [74,75]. When 3T3 cells are exposed briefly 
to proteolytic treatment, the intracellular levels of 
cAMP fall, followed by the onset of DNA synthesis 
several hours later. However, if cAMP is added to 
the cells within 3 min after their exposure to the 
protease, proliferation is blocked. These results 
suggest a cause and effect relationship between the 
decrease in cellular cAMP content and the onset of 
proliferation. 
cAMP can also affect the composition of the cell 
surface as evidenced by alterations in the incorpo-
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ration of radioactive fucose and leucine into certain 
components of cell membranes in the presence of 
cAMP [74,75] . The interrelationship between 
cAMP and the cell surface may be of importance in 
psoriasis. Another component of the cell surface 
that may be of importance in psoriasis is the 
presence of certain HLA antigens [76]. While no 
correlation has been made between the HLA sys-
tem of man and cAMP levels in tissue, such a 
study has been conducted in mice. The H-2 locus 
genotype (histocompatibility complex in the 
mouse) and the cAMP levels in liver appear to be 
associated [77]. A hypothesis might be advanced 
that the genetically occasioned aberrations in the 
HLA system of the psoriatic might predispose such 
a patient to altered cAMP levels in the lesion or in 
the cellular immune system. Such instability could 
permit, either directly in the epidermis or indi-
rectly as a function of the immune system, the 
appearance of a psoriatic lesion. 
Lastly, it is our view that the chalone system as 
originally formulated by Bullough and Lawrence 
[78] is a component of the cell surface [79]. 
Tissue-specific cell surface aggregation factors re -
cently have been purified and described [80]. It is 
possible that homeostasis in an organized tissue 
such as epidermis is mediated by such cell surface 
components. It will be of interest to determine 
whether purified cell surface components alter the 
cyclic nucleotide levels in the cells. 
Molecular and clinical pharmacology of psoria-
sis. One of the primary goals of the research 
conducted in our laboratory is to obtain a thera-
peutic agent which will decrease proliferation and 
increase differentiation in diseases such as psoria-
sis [18, 40, 45 , 81]. Since agents that increase 
intracellular levels of cAMP have been demon-
strated to slow the growth and differentiate mela-
nomas [82], neuroblastomas [59], and transformed 
fibroblast-like cells [7], cAMP may also be effec-
tive in psoriasis. Clinical pharmacologic experi-
ments designed to indicate whether cAMP therapy 
will be efficacious and safe are in progress. Experi-
mental agents are initially screened to determine 
whether alteration in cyclic nucleotide levels 
occurs after incubation of such an agent with 
epidermal slices. Compounds that give a positive 
result are considered for clinical bioassay. At 
present, positive effects have been obtained in a 
double-blind study using topical papaverine [83] as 
well as in an anecdotal study utilizing intramuscu-
lar 5' -AMP [40] . Both compounds elevate cAMP 
levels in epidermal slices [83, 84]. 
Further indications that cAMP therapy may be 
of value in psoriasis were reported by Chinese 
investigators. Dibutyryl cAMP was injected intra-
muscularly with an improvement in the disease for 
22 of the 25 patients without discernible side 
effects [85). Thus the normalization of the cyclic 
nucleotide ratios by manipulating either cAMP or 
cGMP seems to be a reasonable approach to 
pursue. 
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FIG. 2. Sliver biopsy of an involved psoriasis lesion 6 
weeks after being grafted onto a nude mouse demonstrat-
ing the acanthosis. Hemotoxylin on eosin stain ( x 44). 
FUTURE DIRECTIONS 
Future advances In understanding diseases of 
proliferation will almost certainly come through 
heightened knowledge of the fundamental prolifer-
ative mechanisms. It is most likely that in the near 
future tissue culture and cell-free in vitro models 
will be developed which will allow for the dissec-
tion of the role of some of the regulatory factors 
mentioned previously. An animal mode that 
appears particularly suited to the study of psoriasis 
is the nude mouse system developed by Krueger et 
al [86]. Nude mice are genetically athymic and can 
accept grafts of human psoriatic tissue. Figure 2 is 
a histologic section of a psoriatic lesion which was 
grafted on the nude mouse. This system can be 
used to study psoriatic tissue in an environment 
capable of experimental manipulation. 
Additionally, the application of techniques of 
somatic cell genetics to the epidermis promises to 
offer similar potential in the study of proliferative 
regulatory phenomena that have already been 
achieved through the use of bacterial genetics in 
the study of regulatory mechanisms of the Lac 
operon [87]. 
Finally, detailed study of the "proliferative pro-
gram" (e.g., cGMP- and cAMP-mediated en-
zymes) and their physiologic constraints may lead 
to a molecular understanding of proliferative skin 
disease. With increased understanding of the 
molecular pathology of these disorders, specific 
new therapies directed against aberrant prolifera-
tive mechanisms may be achieved. 
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DISCUSSION 
Austen: If PGs are elevated in psoriatic lesions, why is 
cAMP reduced? What are the effects of nonsteroidal 
anti-inflammatory agents on psoriasis? 
Voorhees: Let me first clarify what I previously said 
about the arachidonic acid metabolic cascade in psoria-
sis . Our collaborators (Hammarstrom, Hamberg, and 
Samuelsson) at the Karolinska Institut found a 25-fold 
increase in arachidonic acid, an 80-fold increase in 
HETE, a 40% increase in PGE 2 , and an 86 % increase in 
PGF 2a in lesional epidermis versus clinically uninvolved 
epidermis of patients with psoriasis. All increases were 
statistically significant. So the alternative pathway of 
arachidonic acid metabolism (the HETE pathway) was 
dramatically increased and the classical pathway of 
arachidonic acid conversion by fatty acid cyclo-oxyge-
nase into PGE 2 and PGF 2a via the cyclic endoperoxide 
intermediate was modestly increased. Therefore, it 
appears that in the psoriatic epidermis, arachidonic acid 
goes primarily to HETE and to the classical PGs, PGE 2 
and PGF 2 • 
You ask why PGE 2 was not decreased in the lesion 
since cAMP is decreased. A paper has appeared [J Invest 
Dermatol 64:326, 1975] indicating that PGE biosynthesis 
was decreased in psoriatic lesional epidermis . A reason 
for these findings may be that the very large endogenous 
arachidonate pool diluted the radioactive label such that 
the reduced transformation into PGE was a result of this 
dilution rather than a function of reduced catalytic 
activity of the fatty acid cyclo-oxygenase . We feel that 
there are several possibilities in interpreting the 32% 
elevation, which was statistically significant, in the 
lesions. One possibility is the phenomenon of PG desensi-
tization of PG receptors, which leads to the loss of the 
ability of the tissue to generate cAMP. Newcombe et al 
[proc Natl Acad Sci USA 72:3124, 1975] postulate that in 
situations of severe chronic inflammation or in aberrant 
cellular proliferation, desensitization of PG receptors 
may be important in the regulation of the inflammatory 
or proliferatory response. And indeed, a paper by Aso, 
Oren berg, and Farber [J Invest Dermatol 65:375, 1975] 
Sept.1976 
documents the fact that psoriatic epidermis accumulates 
much less cAMP in response to PGE than does normal 
epidermis. Another possibility is that the F 2a/E2 ratio, 
which is elevated, is more important than the actual 
molar concentrations of the PGs and that the elevated 
F 2a/E2 ratio favors the production of cGMP. In a prelimi-
nary report at the Society for Investigative Dermatology 
in 1975, Aso and his colleagues reported a rise in 
epidermal cGMP, I believe in response to PGF 2a, but we 
have found that simple injury to the epidermis causes a 
rise in cGMP. To my knowledge, the only satisfactory 
data which have been published in any system pertinent 
to the issue of PGF 2a raising cGMP is the work of 
Dunham and Goldberg, wherein the hoYi'ne vein PGF 2a 
raised cGMP levels. Another possibility is that the ele-
vated levels of PG E 2 and PGF 2a interfere with the binding 
to their respective receptors. Lastly, it is possible that 
PGE 2 has nothing to do with the physiologic regulation of 
adenyl ate cyclase and cAMP accumulation in epidermis . 
Our data on the effect of nonsteroidal anti-inflamma-
tory agents on PG availability were gathered in collabora-
tion with the group at the Karolinska Institut. We found 
that indomethacin totally inhibits the production of 
PG E 2 and PG ~ 2a but not the production of HETE. The 
details of this study will appear late in 1976 in the Pro-
ceedings of the National Academy of Sciences. Based on 
the modest increases in the PGs that have been meas-
ured in our study, I would seriously doubt whether the 
nonsteroid anti-inflammatory agents would have any-
thing to offer. I would expect that in vivo you would 
find the same thing as in vitro, i.e., indomethacin in 
the system might cause a pile-up of arachidonic acid 
and HETE. This would not improve the lesions and 
might even make them worse. 
Kirkpatrick: Does the effect of phototherapy on 
psoriasis fit into your cyclic nucleotide model? 
Voorhees: As some of you know, we reported back in 
1973 that UVA and psoralen inhibits epidermal DNA 
synthesis and that when topically applied psoralen was 
exposed to UV A, the psoriatic lesions would clear. This 
information was then useo. by the group at Harvard to 
develop the elegant light system and the new dosage 
schedule using systemic psoralens (which today has been 
made into a practical form of therapy) known as photo-
chemotherapy, thus being far more effective than our 
original observations . The only information of which I am 
aware which bears on the possible interrelationship of 
photochemotherapy and cAMP was presented at the 1974 
Spring Meeting of the American Federation for Clinical 
Research by Martin Carter of Yale; he showed that UV A 
plus psoralen, when added to melanoma cells in vitro, 
produced a fairly respectable rise in the cellular levels of 
cAMP. I have a feeling that there is more to the 
molecular basis of photochemotherapy action than a 
simple inhibition of DNA synthesis. Whether this 
involves cAMP is a question for the future. 
With respect to the role of cAMP and skin cancer, 
there have been several reports on this issue, the best of 
'Nhich was by Belman and Troll [Cancer Res 34:3446, 
1974], in which they showed that the topical application 
of dibutyryl cAMP and/or theophylline would block the 
formation of skin c,ancer in an in vivo model of 2-stage 
carcinogenesis using a polycyclic hydrocarbon as the 
initiator and phorbol ester as the promoter. 
Gigli: Would y()u please comment on the recent 
publication that immunoglobulins have been seen in the 
epidermis in psoriatic plaques. 
Voorhees: I am aware of three lines of evidence which 
bear on this point: (1) the elevated incidence of HLA 13 
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and 17 in patients with psoriasis and the known relation 
of the immune response gene products to the HLA cell 
surface gene products; (2) the recent demonstration by 
Krueger that patients with psoriasis are significantly less 
sensitized by a standardized dose of DNCB than are 
controls; (3) the work of Beutner from Buffalo on a 
particular type of epidermal immunofluorescent staining 
in psoriasis. The arthritis which sometimes accompanies 
psoriasis also suggests the possibility of an immunologic 
abnormality. One of the problems in trying to work out 
the possibility of immunologic aberrations in the skin 
lesions of psoriasis is the fact that the lesions and the 
epidermal cells in the lesions are bathed by serum 
proteins . Using the suction blister technique on the 
psoriatic lesion we got about 2 or 3 ml of serum whereas 
the uninvolved areas developed a very nice suction 
blister. There are other studies in the literature which 
show that both by biochemical and immunochemical 
techniques many different serum components are ex-
tractable from lesional epidermis. Therefore, antibodies 
and possibly components of the complement system that 
are situated in the epidermis might have nothing what-
ever to do with the pathogenesis of the disease. 
Jordon: I have not seen similar staining in psoriatic 
skin lesions. I am afraid I cannot say whether it is specific 
deposition or just artifact at this time. 
Bystryn: There are two remarks that can be made on 
the basis of Dr. Beutner's work regarding the role of 
immunity in psoriasis. The first is that most normal 
persons have circulating antibodies to normal antigens in 
the stratum corneum. The second is that these antibodies 
can be found, together with complement, bound in vivo 
in the stratum corneum of psoriasis lesions but not in 
normal skin. 
Turk: Would you comment on the possible immuno-
logic significance of the mononuclear leukocyte infiltrate 
in the dermis? Could epidermal proliferation result from 
a factor released by an immunologic reaction in the 
dermis? 
Voorhees: The predominantly mononuclear infiltrate 
in a stable lesions of psoriasis probably means something. 
I would guess that the psoriatic epidermis is liberating 
many of the proteases that Dr. Lazarus has been talking 
about, and these entering the dermis of a lesion would 
potentially be triggers of an inflammatory response 
manifested by a cellular infiltrate. Certainly mononu-
clear infiltrates are not specific for psoriasis inasmuch as 
they are seen in a wide variety of diseases. It is a 50/50 
proposition at this point in terms of whether the disease is 
primarily epidermal or primarily dermal. Our research is 
directed at the epidermis because if we can get an area 
which is sufficiently central to the regulation of prolifera-
tion and differentiation, we might be able to restore 
epidermal homeostasis . 
Bystryn: Since IgG and complement are apparently 
fixed in the stratum corneum of psoriatic skin, one 
explanation for the presence of leukocytes in lesions of 
this disease is that they are attracted there by comple-
ment activation. 
Braverman: In psoriasis there is a migration of 
neutrophils from the venous capillaries in the tip of the 
dermal papilla into the stratum corneum where they form 
Munro's microabscesses. This is a distinctive feature of 
psoriatic histopathology. At the same time there is an 
accumulation of mononuclear cells around the venules in 
the horizontal dermal plexus. One has to account for the 
movements of these two different cell populations: There 
could be some chemotactic factor in the epidermis that is 
attracting the neutrophils. This attraction is very marked 
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in pustular psoriasis of Von Zumbusch, with resulting 
gross lakes of pus developing on the surface of the skin. 
Voorhees: Obviously bacteria and complement com-
ponents and other factors are chemotactic for neutro-
phils. It would be my opinion that the microabscesses 
represent epiphenomena and probably do not have much 
to do with the pathophysiology of the disease, either from 
the point of view of the initiation and/or the maintenance 
of the lesion . In making that statement, I am talking 
about the neutrophils that are situated in the Munro 's 
microabscesses. This does not say that neutrophils with 
their accompanying proteases might not be important in 
stimulating the basal cells to divide early on in the course 
of the development of the lesion . It just seems to me that 
once they are loculated high in a microabscess just 
beneath the parakeratotic stratum corneum that they are 
not likely to be of much pertinence to the molecular 
pathology of the lesion. As long as we are talking about 
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the possibility of why neutrophils are high in the epider-
mis in this lesion, I could make the argument that they 
migrate there in response to a cGMP gradient. We have 
shown (in collaboration with Nelson Goldberg) that 
cGMP levels are elevated in the lesion, and Goldberg and 
his colleagues [Nature (Lond) 245:458, 1973] recently 
showed that polymorphonuclear leukocytes will migrate 
towards cGMP in a Boyden chamber. 
Sams: The keratinous proteins of stratum corneum, 
hair, and nails reside in an immunologically privileged 
site, at least until this site is breached by trauma or 
disease. Thus, many normal individuals, or those with a 
variety of cutaneous diseases, may develop antibodies to 
stratum corneum. Additionally, the stratum corneum is 
an end product of the maturation of epidermal cells. 
Therefore, although antibodies to stratum corneum pro-
teins may indeed occur in psoriasis, it is not possible to 
conceptualize their having a primary role. 
